Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1999 Sep;65(3):902–909. doi: 10.1086/302531

Transmitting genetic risk information in families: attitudes about disclosing the identity of relatives.

J T Wilcke 1, N Seersholm 1, A Kok-Jensen 1, A Dirksen 1
PMCID: PMC1377994  PMID: 10441594

Abstract

Attitudes about disclosing the identities of family members to a physician to ensure diffusion of genetic risk information within affected families were examined in a questionnaire study of Danish patients with alpha1-antitrypsin deficiency (A1AD), their relatives, and a control group of Danish citizens. The questionnaires were returned by 1,761 (82%) of 2,146 recipients; 1,609 (75%) agreed to participate and completed the questionnaire. Only 2.8% objected to disclosing the identity of children, 9.1% objected to disclosing the identity of parents, and 6.7% objected to disclosing the identity of siblings. When genetic tests are offered to a sister, 75.4% of screened individuals with severe A1AD (phenotype "piZ") and 66.8% of piZ probands thought that the physician should say who is ill. Important reasons for informing a sister at risk were, for 58%, the opportunity to prevent disease and, for 41% of piZ-probands, the opportunity to maintain openness in the family and to avoid uncertainty. Stepwise logistic regression of background variables showed that relatives were those for whom most respondents approved the disclosure of the parents' and siblings' identities to enable the physician to examine them for the presence of A1AD. Women were less prone to disclose the identity of siblings. The results indicate that the genetic counselor should inquire about relatives' identities, to ensure that they are properly informed about the known risk of severe genetic disorder, such as A1AD, for which disability can be prevented by a change of lifestyle or by careful management. Disease prevention is essential, but openness and avoidance of uncertainty in affected families are also important. Our findings imply that fully informing all relatives about the disorder and about who is actually ill should be the principal rule.

Full Text

The Full Text of this article is available as a PDF (241.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen L. K., Jensen H. K., Juul S., Faergeman O. Patienters holdning til opsporing af arvelig sygdom. Heterozygot familiaer hyperkolesterolaemi. Ugeskr Laeger. 1998 Oct 12;160(42):6075–6081. [PubMed] [Google Scholar]
  2. Benkendorf J. L., Reutenauer J. E., Hughes C. A., Eads N., Willison J., Powers M., Lerman C. Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility. Am J Med Genet. 1997 Dec 19;73(3):296–303. doi: 10.1002/(sici)1096-8628(19971219)73:3<296::aid-ajmg13>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  3. Berg D., Hirsh H. L. Duty to recall. South Med J. 1980 Aug;73(8):1041-3, 1045. doi: 10.1097/00007611-198008000-00025. [DOI] [PubMed] [Google Scholar]
  4. Biesecker B. B., Boehnke M., Calzone K., Markel D. S., Garber J. E., Collins F. S., Weber B. L. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA. 1993 Apr 21;269(15):1970–1974. [PubMed] [Google Scholar]
  5. Bloch M., Adam S., Wiggins S., Huggins M., Hayden M. R. Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet. 1992 Feb 15;42(4):499–507. doi: 10.1002/ajmg.1320420416. [DOI] [PubMed] [Google Scholar]
  6. Bratt O., Kristoffersson U., Lundgren R., Olsson H. Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing. Urology. 1997 Sep;50(3):360–365. doi: 10.1016/S0090-4295(97)00250-1. [DOI] [PubMed] [Google Scholar]
  7. Buist A. S. Alpha 1-antitrypsin deficiency--diagnosis, treatment, and control: identification of patients. Lung. 1990;168 (Suppl):543–551. doi: 10.1007/BF02718177. [DOI] [PubMed] [Google Scholar]
  8. Eriksson S., Carlson J., Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986 Mar 20;314(12):736–739. doi: 10.1056/NEJM198603203141202. [DOI] [PubMed] [Google Scholar]
  9. Hayes C. V. Genetic testing for Huntington's disease--a family issue. N Engl J Med. 1992 Nov 12;327(20):1449–1451. doi: 10.1056/NEJM199211123272008. [DOI] [PubMed] [Google Scholar]
  10. Huggins M., Bloch M., Wiggins S., Adam S., Suchowersky O., Trew M., Klimek M., Greenberg C. R., Eleff M., Thompson L. P. Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet. 1992 Feb 15;42(4):508–515. doi: 10.1002/ajmg.1320420417. [DOI] [PubMed] [Google Scholar]
  11. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand. 1978;204(5):345–351. doi: 10.1111/j.0954-6820.1978.tb08452.x. [DOI] [PubMed] [Google Scholar]
  12. McAbee G. N., Sherman J., Davidoff-Feldman B. Physician's duty to warn third parties about the risk of genetic diseases. Pediatrics. 1998 Jul;102(1 Pt 1):140–142. doi: 10.1542/peds.102.1.140. [DOI] [PubMed] [Google Scholar]
  13. McNeil T. F., Harty B., Thelin T., Aspegren-Jansson E., Sveger T. Identifying children at high somatic risk: long-term effects on mother-child interaction. Acta Psychiatr Scand. 1986 Dec;74(6):555–562. doi: 10.1111/j.1600-0447.1986.tb06284.x. [DOI] [PubMed] [Google Scholar]
  14. Merz J. F., Cho M. K., Sankar P. Familial disclosure in defiance of nonconsent. Am J Hum Genet. 1998 Sep;63(3):898–900. doi: 10.1086/302025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  16. Nielsen O. H., Thomsen B. L., Green A., Andersen P. K., Hauge M., Schiøtz P. O. Cystic fibrosis in Denmark 1945 to 1985. An analysis of incidence, mortality and influence of centralized treatment on survival. Acta Paediatr Scand. 1988 Nov;77(6):836–841. doi: 10.1111/j.1651-2227.1988.tb10765.x. [DOI] [PubMed] [Google Scholar]
  17. Seersholm N., Kok-Jensen A., Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994 Jul;49(7):695–698. doi: 10.1136/thx.49.7.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Seersholm N., Kok-Jensen A. Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):369–373. doi: 10.1164/ajrccm.151.2.7842193. [DOI] [PubMed] [Google Scholar]
  19. Stoller J. K., Smith P., Yang P., Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994 Nov-Dec;61(6):461–467. doi: 10.3949/ccjm.61.6.461. [DOI] [PubMed] [Google Scholar]
  20. Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand. 1988 Nov;77(6):847–851. doi: 10.1111/j.1651-2227.1988.tb10767.x. [DOI] [PubMed] [Google Scholar]
  21. Thelin T., McNeil T. F., Sveger T. Identifying children at high somatic risk (alpha 1 antitrypsin deficiency): possible long-term effects on parents' reproduction, marital status and social class level. Acta Psychiatr Scand. 1985 Jun;71(6):636–643. doi: 10.1111/j.1600-0447.1985.tb02559.x. [DOI] [PubMed] [Google Scholar]
  22. Thomsen O. O., Wulff H. R., Martin A., Singer P. A. What do gastroenterologists in Europe tell cancer patients? Lancet. 1993 Feb 20;341(8843):473–476. doi: 10.1016/0140-6736(93)90218-6. [DOI] [PubMed] [Google Scholar]
  23. Tibben A., Frets P. G., van de Kamp J. J., Niermeijer M. F., Vegter-van der Vlis M., Roos R. A., van Ommen G. J., Duivenvoorden H. J., Verhage F. Presymptomatic DNA-testing for Huntington disease: pretest attitudes and expectations of applicants and their partners in the Dutch program. Am J Med Genet. 1993 May 1;48(1):10–16. doi: 10.1002/ajmg.1320480105. [DOI] [PubMed] [Google Scholar]
  24. Wiggins S., Whyte P., Huggins M., Adam S., Theilmann J., Bloch M., Sheps S. B., Schechter M. T., Hayden M. R. The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med. 1992 Nov 12;327(20):1401–1405. doi: 10.1056/NEJM199211123272001. [DOI] [PubMed] [Google Scholar]
  25. Wilcke J. T. Late onset genetic disease: where ignorance is bliss, is it folly to inform relatives? BMJ. 1998 Sep 12;317(7160):744–747. doi: 10.1136/bmj.317.7160.744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Winter P. R., Wiesner G. L., Finnegan J., Bartels D., LeRoy B., Chen P. L., Sellers T. A. Notification of a family history of breast cancer: issues of privacy and confidentiality. Am J Med Genet. 1996 Dec 2;66(1):1–6. doi: 10.1002/(SICI)1096-8628(19961202)66:1<1::AID-AJMG1>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  27. Wu M. C., Eriksson S. Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ. J Clin Epidemiol. 1988;41(12):1157–1165. doi: 10.1016/0895-4356(88)90019-4. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES